eribulin

Also known as 2-(3-Amino-2-hydroxypropyl)hexacosahydro-3-methoxy- 26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy- 7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6) pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4H)-one, eribulin mesylate, L01XX41, ER-086526,

Key facts

Drug.Verifiedfields: changed
Drug.verifiedrevid: 461094948
Drug.image: Eribulin.svg
Drug.image_class: skin-invert-image
Drug.width: 300
Drug.USAN: eribulin mesylate
Drug.JAN: eribulin mesilate
Drug.tradename: Halaven, Mevlyq
Drug.MedlinePlus: a611007
Drug.DailyMedID: Eribulin
Drug.pregnancy_AU: D
Drug.routes_of_administration: Intravenous
Drug.class

~4 min read

Article

5 sections

Contents

Medical uses
Adverse effects
Structure and mechanism
Research
References

Eribulin, sold under the brand name Halaven among others, is an anti-cancer medication used to treat breast cancer and liposarcoma.

The most common side effects include fatigue, nausea, hair loss (alopecia), constipation, certain nerve damage causing weakness or numbness in the hands and feet (peripheral neuropathy), abdominal pain and fever (pyrexia). Eribulin may also cause low levels of infection-fighting white blood cells (neutropenia) or decreased levels of potassium or calcium.